Skip to content
Review Open access

Implementation of genetic counseling recommendations in an MTB setting.

Oct 2026 · JCO Oncology Practice · Vol 22, pp. 68-68 · 0 citations

TL;DR

This study aimed to determine qualifiers for GC recommendations and quantify the patients who subsequently underwent germline testing (GT) and analyze the evolution in GC recommendations as somatic testing has become more widespread.

Abstract

68 Background: Genetic counseling (GC) is a critical component of precision oncology and personalized cancer care, informing on targeted treatment strategies, cancer surveillance, and familial risk. The Molecular Tumor Board (MTB) serves as a multidisciplinary forum where GC recommendations are generated. Effective communication between the MTB and GC team ensures timely referral and follow-up. This study aimed to determine qualifiers for GC recommendations and quantify the patients who subsequently underwent germline testing (GT). Methods: We analyzed GC recommendations based on somatic testing and review of personal and family cancer histories for patients reviewed at the MTB from May 2021 to December 2025. Recommendations for GC were generated in alignment with institutional protocols informed by the guidelines proposed by Li et al., 2020 in Genetics in Medicine and McVeigh et al., 2025 in J Med Genet, taking variant allele frequency (VAF) and gene of interest actionability into account. Recommendations were communicated to treating oncologists for clinical judgement and appropriate referrals. Recommendations were assigned a descriptive category for analysis. GT outcomes were obtained through chart review to assess implementation of recommendations. Results: Of the 5405 unique patients reviewed by the MTB, 1764 were identified as patients that qualified for GC. Of these patients, 993 (56.3%) underwent GT with 221 (12.5%) completing GT within Inova following recommendations. Most patients met more than one criterion for GT, with diagnosis, according to relevant NCCN guidelines, being the most common driver for recommendation. Of the 221 patients who completed GT at Inova following MTB review, 45 patients were found to have pathogenic variants in genes associated with an autosomal dominant hereditary cancer susceptibility and 5 were found to be carriers for autosomal recessive cancer susceptibility conditions. Pathogenic variants in the BRCA2 gene were most common among these patients. Conclusions: Effective collaboration between clinical providers and GC teams is essential to ensure that patients are appropriately evaluated for GC needs. The MTB serves as a structured forum that facilitates coordinated decision-making across these disciplines. Further investigation is warranted to understand the factors influencing providers’ decisions to concur with referral requests for follow-up GC following MTB review, as well as to analyze the evolution in GC recommendations as somatic testing has become more widespread. GC recommendations by reason. Reason # Patients Somatic Mutation of Interest or Somatic Mutation at High VAF (≥30%) 125 (7.1%) Personal Diagnosis (Including Early Onset Disease and/or Multiple Primaries) 420 (23.8%) Family History 99 (5.6%) Combination of Qualifiers 167 (9.5%) Already Contacted/ Referred 384 (21.8%) Already Seen/Tested 557 (31.6%) Additional Testing Recommended 12 (0.7%) Total 1764

Read PDF

Similar papers

Open access Oct 2026

Implementation needs for expanding oncologist-led germline genetic testing: A qualitative analysis of patients and clinicians.

69 Background: Germline genetic testing (gGT) is increasingly important in oncology, enabling intensified surveillance and risk-reducing strategies for high-risk individuals and targeted therapies for patients with cancer. As testing eligibility expands, mainstream gGT by non-geneticist clinicians is being adop...

Vicky Ro, Zoë Bell, Marcely Ventura et al. · 0 citations
Open access Sep 2026

Bridging the gap between guidelines and practice: genetic counseling uptake and barriers in patients with ovarian malignancies

Genetic counseling and germline genetic testing are essential components of ovarian cancer care; however, their implementation in routine clinical practice remains inconsistent. This study aimed to evaluate the utilization of genetic counseling and testing among patients with ovarian cancer and identify barriers to imp...

W. Shaalan, N. Dikow, F. Kommoss et al. · 0 citations
Review Open access Oct 2026

Improving germline genetic testing and genetic counseling referral in prostate, pancreatic, and colorectal cancer through a multidisciplinary quality improvement intervention.

580 Background: Germline testing (GLT) identifies hereditary cancer syndromes and informs precision oncology care. NCCN guidelines recommend genetic evaluation for all patients with pancreatic cancer (Panc), those with high-risk or metastatic prostate cancer (PCa), and select patients with colorectal cancer (CR...

Yusra B. Medik, Evgeniya Pasternak, Trilok Shrivastava et al. · 0 citations
Open access Oct 2026

Genetic Testing and Counselling in Breast Cancer: Practice-based data from an Italian Tertiary Centre

Abstract Background Integration of germline genetic testing with clinical genetic counselling is essential to guide prevention, surveillance, and personalised treatment in breast cancer. However, real-world implementation and access remain variable. We evaluated the impact of a structured genetic programme in a tertiar...

M. Dajko, V. Rossi, D. Di Giacomo et al. · 0 citations
Review Open access Oct 2026

Eliminating barriers to uptake of germline genetic testing for patients with advanced cancer: the GTAC study

As germline genetic testing indications expand, barriers to testing persist. We evaluated the feasibility of a novel approach in which patients with cancer underwent genetic testing first, with follow-up genetic counseling only for those found to have a germline pathogenic variant (PV). Patients with advan...

Kara K. Landry, W. Mckinnon, Heather M. Feldman et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.